PTMI
I don’t see your proposal on reduced trial fees for priority access post approval as feasible for the following reasons
1) I don’t think that if approved that CYDY will be able to control distribution to select hospitals that participated in trials for the following reasons
- this would have the wrong kind of optics - promising preference for a life saving drug to hospitals running the trials that leads to approval
- I believe that the government is controlling the distribution of the current standard of care drug and CYDY will need this kind of guidance because it doesn’t have a sales and distribution function for the covid indication (Vyera only has access to HIV in the US)

2) hospitals will not want to reduce their fees for trial participation
- elective surgeries are down so hospital profitability is affected and this revenue is very helpful to hospitals top lines
- there are signed contracts for these trials that would need to be changed and the approval for that at the hospitals will be hard to get

IMO